An ecosystem of innovative startups
How the Institut Pasteur sows the seeds of future innovations
By founding its first spin-off (a company set up based on knowledge and technology derived from research) in 1997, the Institut Pasteur established its credentials as a pioneering supporter of biotechnology entrepreneurship. For over 25 years, we have been supporting early-stage companies that develop medical innovations to protect human health.
To date, the Institut Pasteur has helped launch and/or grow more than 37 startups which draw on the technologies and expertise developed by our research teams.
Each of these companies is imbued with some of the Institut Pasteur's excellence and continues, in its own way, to meet major health challenges, whether in the field of cancer research, immunology, infectious diseases or precision medicine.
Startups spun out of our laboratories
These companies, which originated in Institut Pasteur laboratories, are now developing tomorrow's therapies and technologies.
-
Launched: 2025. A spin-off from the Institut Pasteur's laboratories, Enodia Therapeutics develops novel therapeutic approaches targeting DNA repair mechanisms. This represents a promising avenue, with oncology applications.
-
Launched: 2020. AVATAR MEDICAL™ is revolutionizing surgical planning using medical virtual reality. Its solutions allow 3D visualization and exploration of each patient's specific anatomy by physicians prior to surgery.
-
Oncovita develops innovative therapeutic vaccines drawing directly on technologies derived from Institut Pasteur research.
-
Launched: 2010. Core business: investigating Nanofitins for target capture with a view to developing innovative therapeutic imaging solutions.
-
Launched: 2003. Core business: developing and commercializing computer analysis tools to help with therapeutic decision-making.
-
Launched: 2024. Core business: kits to detect and quantify biomarkers for infectious agents.
-
Launched: 2011. Core business: developing rapid dipstick tests to guide diagnosis, particularly for meningitis, dysentery and cholera.
-
Launched: 1999. Core business: developing technologies to operate directly and precisely on DNA.
-
Launched: 2015. Core business: groundbreaking DNA synthesis technology coding any living being.
-
Launched: 2014. Core business: developing therapeutic agents to tackle resistant bacteria.
-
Launched: 1999. Core business: genetic design used to create high-level genetically modified mouse, rat and cell line models for academic and biopharmaceutical researchers.
-
Launched: 1998. Core business: a biopharmaceutical company involved in research and development of new targets and therapies for the treatment of cancer.
-
Launched: 2010. Core business: developing immunotherapies to treat cancer.
-
Launched: 2018. Core business: developing, manufacturing and commercializing neuroprotective and neuroregenerative molecules targeting eye and central nervous system diseases.
-
Okomera, founded in 2020, is a pioneer in the automation and miniaturization of personalized tumor biopsy studies.
-
Launched: 2010. Core business: Providing services for GMP-grade biopharmaceutical quality control tests based on next generation sequencing (NGS) for viral safety and genetic characterization.
-
Launched: 2008. Core business: novel anti-infective, anti-inflammatory and anti-cancer therapeutic solutions.
-
A biotechnology company, co-founded by Truffle Capital and the Institut Pasteur, whose purpose is to develop an effective treatment for SARS-CoV2 and its main variants.
-
Launched: 2003. Core business: viral safety testing of proprietary biotherapeutic proteins, biotherapeutic development, cell banking and immunology support.
-
Core business: developing vaccines based on lentiviral vectors (cancer, HIV) in the fields of immunization and immunotherapy.
-
Core business: working towards the development of an mRNA-expressed pediatric dengue vaccine.